Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886160 | 1.00 | TACR3 (0.51) | TACR3NAMPTHRH3MAPTKDM4E | |
| SCHEMBL4846419 | 0.90 | MAPT (0.51) | NAMPTHRH3MAPTKDM4ETHRB | |
| SCHEMBL19702757 | 0.89 | DPP4 (0.55) | NAMPTHRH3MAPTKDM4ETHRB | |
| SCHEMBL4735264 | 0.89 | NAMPT (0.54) | NAMPTMAPTKDM4ETHRBSTS | |
| SCHEMBL19703142 | 0.87 | GPR119 (0.55) | NAMPTMAPTKDM4ETHRBSTS | |
| SCHEMBL30493305 | 0.86 | NAMPT (0.52) | NAMPTHRH3MAPTKDM4ETHRB | |
| SCHEMBL20347002 | 0.86 | NAMPT (0.52) | NAMPTHRH3MAPTKDM4ETHRB | |
| SCHEMBL19703149 | 0.86 | NAMPT (0.52) | NAMPTMAPTKDM4ETHRBSTS | |
| SCHEMBL29257963 | 0.86 | DPP4 (0.50) | NAMPTHRH3MAPTKDM4ETHRB | |
| SCHEMBL25202591 | 0.85 | NAMPT (0.51) | NAMPTMAPTKDM4ETHRBSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | TACR3 1406/4885NAMPT 2432/4885HRH3 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.